|
|||||
|
|
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial |
|
| Authors: | Christoph Wanner MD Silvio E. Inzucchi MD Bernard Zinman MD Audrey Koitka-Weber PhD Michaela Mattheus Dipl Biomath Jyothis T. George MD Maximilian von Eynatten MD Sibylle J. Hauske MD EMPA-REG OUTCOME Investigators |
| Affiliation: | 1. Department of Medicine, Division of Nephrology, Wuerzburg University Clinic, Wuerzburg, Germany;2. Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA;3. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada;4. Department of Medicine, Division of Nephrology, Wuerzburg University Clinic, Wuerzburg, Germany Boehringer Ingelheim International GmbH, Ingelheim, Germany Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia;5. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;6. Boehringer Ingelheim International GmbH, Ingelheim, Germany;7. Boehringer Ingelheim International GmbH, Ingelheim, Germany Vth Department of Medicine, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany |
| Abstract: | |
| Keywords: | cardiovascular disease clinical trial diabetic nephropathy empagliflozin sodium-glucose co-transporter-2 inhibitor type 2 diabetes |